Covered recipient · General Payments record
ALEXANDER PIASECKI
Physician Assistants & Advanced Practice Nursing Providers Nurse Practitioner Family
General Payments · PY2021–2024
$2,766.54
- Reported across 189 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $231.46 | 15 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Axsome Therapeutics, Inc. | $30.38 | 2 |
| GlaxoSmithKline, LLC. | $30.30 | 2 |
| Lilly USA, LLC | $29.94 | 2 |
| Acerta Pharma LLC | $28.90 | 2 |
| ABBVIE INC. | $19.70 | 1 |
| Averitas Pharma Inc. | $17.33 | 1 |
| Astellas Pharma US Inc | $16.70 | 1 |
| Novo Nordisk AS | $15.65 | 1 |
| Amgen Inc. | $15.20 | 1 |
| Corcept Therapeutics | $13.85 | 1 |
| PFIZER INC. | $13.51 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (15)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $19.70 | 02/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107848873 | CMS |
| Amgen Inc. | $15.20 | 05/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116017591 | CMS |
| Astellas Pharma US Inc | $16.70 | 02/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139463172 | CMS |
| AstraZeneca Pharmaceuticals LP | $13.61 | 02/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105309785 | CMS |
| AstraZeneca Pharmaceuticals LP | $15.29 | 03/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105889351 | CMS |
| Averitas Pharma Inc. | $17.33 | 04/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133467236 | CMS |
| Axsome Therapeutics, Inc. | $16.25 | 06/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1148330763 | CMS |
| Axsome Therapeutics, Inc. | $14.13 | 06/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1148330765 | CMS |
| Corcept Therapeutics | $13.85 | 10/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117773201 | CMS |
| GlaxoSmithKline, LLC. | $15.85 | 02/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116733404 | CMS |
| GlaxoSmithKline, LLC. | $14.45 | 03/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116725832 | CMS |
| Lilly USA, LLC | $15.22 | 01/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135444403 | CMS |
| Lilly USA, LLC | $14.72 | 05/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135444405 | CMS |
| Novo Nordisk Inc | $15.65 | 01/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100241832 | CMS |
| PFIZER INC. | $13.51 | 02/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131000617 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.